NONOF Projected Dividend Yield
Cl B Ord/Novo-Nordisk AS ( OTCBB : NONOF )Novo-Nordisk is a healthcare company focuses on diabetes care. Co. is engaged in the discovery, development, manufacturing and marketing of pharmaceutical products and has two segments: diabetes and obesity care and biopharm. Co. has one diabetes product portfolios, including insulin, a portfolio of modern insulin and human insulin as well as a portfolio of GLP-1 receptor agonists administered both via subcutaneous injection and as a tablet. Co.'s first product to treat obesity is Saxenda®. Co.'s second obesity treatment product is Wegovy®. In addition, Co.'s marketed portfolio includes haemophilia and growth hormone therapies. 20 YEAR PERFORMANCE RESULTS |
NONOF Dividend History Detail NONOF Dividend News NONOF Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend Amount (DKK) |
2024 |
N/A |
N/A |
Mar 25, 2024 |
Mar 26, 2024 |
6.4000 |
2024 Total: |
6.4000 |
||||
2023 |
N/A |
N/A |
Aug 21, 2023 |
Aug 22, 2023 |
3.0000 |
2023 |
N/A |
N/A |
Mar 27, 2023 |
Mar 28, 2023 |
4.0750 |
2023 Total: |
7.0750 |
||||
2022 |
N/A |
N/A |
Aug 15, 2022 |
Aug 16, 2022 |
2.1250 |
2022 |
N/A |
N/A |
Mar 28, 2022 |
Mar 29, 2022 |
3.4500 |
2022 Total: |
5.5750 |
||||
2021 |
N/A |
N/A |
Aug 17, 2021 |
Aug 18, 2021 |
1.7500 |
2021 |
N/A |
N/A |
Mar 29, 2021 |
Mar 30, 2021 |
2.9250 |
2021 Total: |
4.6750 |
||||
2020 |
N/A |
N/A |
Aug 17, 2020 |
Aug 18, 2020 |
1.6250 |
2020 |
N/A |
N/A |
Mar 30, 2020 |
Mar 31, 2020 |
2.6750 |
2020 Total: |
4.3000 |
||||
2019 |
N/A |
N/A |
Aug 19, 2019 |
Aug 20, 2019 |
1.5000 |
2019 |
N/A |
N/A |
Mar 25, 2019 |
Mar 26, 2019 |
2.5750 |
2019 Total: |
4.0750 |